New drug combo aimed at tough cancers pulled before starting
NCT ID NCT07328490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a combination of two drugs—tarlatamab and sacituzumab govitecan—in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to find a safe dose and see if the drugs could shrink tumors. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tarlatamab and sacituzumab govitecan
- What this could lead to
- If it works, this could point toward a new treatment option for aggressive lung and neuroendocrine cancers that have stopped responding to standard therapy.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness exist. The combination may cause significant side effects, and it is unknown if it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Could a PARP inhibitor boost chemo for tough lung cancer?
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer